Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25896635 | 0.91 | SIGMAR1 (0.49) | SIGMAR1SLC6A3MEN1KMT2A | |
| SCHEMBL21910398 | 0.88 | SIGMAR1 (0.48) | SIGMAR1MEN1KMT2A | |
| SCHEMBL21911488 | 0.84 | SIGMAR1 (0.48) | SIGMAR1 | |
| SCHEMBL6495242 | 0.78 | SIGMAR1 (0.54) | SIGMAR1SLC6A3KCNH2 | |
| SCHEMBL23579037 | 0.76 | SIGMAR1 (0.47) | SIGMAR1MEN1KMT2AKCNH2 | |
| SCHEMBL25138149 | 0.76 | TACR1 (0.41) | MEN1KMT2AHDAC2 | |
| SCHEMBL21910684 | 0.76 | SIGMAR1 (0.46) | SIGMAR1SLC6A3KCNH2 | |
| SCHEMBL21910678 | 0.75 | SIGMAR1 (0.41) | SIGMAR1GAAMEN1KMT2A | |
| SCHEMBL21910438 | 0.75 | SIGMAR1 (0.41) | SIGMAR1SLC6A3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27171281 | 0.75 | SIGMAR1 (0.41) | SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454531-B2 | Substituted piperazine derivatives useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-28 | — | — | US | disclosed |
| CN-115175907-B | Substituted piperazine derivatives useful as T cell activators | 百时美施贵宝公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20230118629-A1 | SUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230118629-A1 | SUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-20 | — | — | US | disclosed |
| CN-115175907-A | Substituted piperazine derivatives useful as T cell activators | 百时美施贵宝公司 | 2022-10-11 | — | — | CN | disclosed |
| WO-2021133749-A1 | SUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230118629-A1 | SUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | SIGMAR1 2423/4885SLC6A3 4144/4885GAA 2836/4885 |
| US-12454531-B2 | Substituted piperazine derivatives useful as T cell activators | DGKZ, DGKA, DGKG | SIGMAR1 2423/4885SLC6A3 4144/4885GAA 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.